Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $49.02, for a total value of $151,962.00. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at $2,070,898.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total value of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Performance

RXST stock opened at $47.15 on Wednesday. The firm has a market cap of $1.74 billion, a PE ratio of -37.42 and a beta of 1.22. The firm’s 50 day moving average price is $51.16 and its 200-day moving average price is $53.90. RxSight, Inc. has a one year low of $20.66 and a one year high of $66.54.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The business’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.40) EPS. Equities research analysts predict that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RXST. Oppenheimer lowered their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus decreased their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. BTIG Research raised their target price on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Finally, Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $60.14.

Institutional Trading of RxSight

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RXST. Marshall Wace LLP purchased a new stake in RxSight in the second quarter valued at approximately $19,512,000. Driehaus Capital Management LLC raised its position in RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the period. Baillie Gifford & Co. raised its position in RxSight by 438.8% in the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after purchasing an additional 291,733 shares during the period. William Blair Investment Management LLC purchased a new stake in RxSight in the second quarter valued at approximately $14,942,000. Finally, M&G Plc purchased a new stake in RxSight in the first quarter valued at approximately $7,354,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.